Optibiotix Health Plc (LON:OPTI) CEO Stephen OHara today spoke about an article published in the telegraph. The article refers to a major Lancet study which backed the safety of statins where according to a group of medics underestimated the side-effects and said the study was ‘fundamentally flawed.’
Stephen OHara, OptiBiotix Health Plc CEO said: ‘This article reflects a growing concern over the side affects from statins. This can lead to high level of non compliance with some studies showing this to be a high as 40% after 2 years. Whilst many users will benefit from statins concerns over side affects and compliance means there is a growing gap between patient’s requirements and clinical practice, with the limitations of current approaches increasing interest in alternative treatment options. OptiBiotix products work by different mechanism of action to statins and will provide a range of cardiovascular products to reduce both LDL cholesterol and blood pressure, two factors known to increase cardiovascular risk. These products have the potential to provide a safe alternative or supplement to existing options to reduce cardiovascular risk’.
